Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05876377 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

StatusTerminated
PhaseNot specified
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Reclassified as terminated (was completed) Sponsor's reason: Study discontinued due to questions of data validity and bias in data which would limit causal inference and estimation of vaccine effectiveness.
    • Eligibility criteria expanded, about 41 words
  2. Trial completed
    • Study completion moved earlier from Sep 30, 2026 to May 31, 2026
    v21
  3. Primary completion date: Sep 9, 2025 to May 31, 2026v20 Show 4 more changesShow less
    • Trial status: Completed to Active, Not Recruiting
    • Study completion date: Sep 9, 2025 to Sep 30, 2026
    • Study description revised
    • Eligibility criteria expanded, about 4 words
  4. Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates changed from estimate of Dec 31, 2025 to Sep 9, 2025
    v19
  5. 3 versions Re-verified since Aug 4, 2025, no change to tracked fieldsv16-v18
Show 14 earlier versionsHide 14 earlier versions
  1. Eligibility criteria expanded, about 45 words
    • Study description expanded, about 10 words
    v15
  2. 4 versions Re-verified since Apr 15, 2025, no change to tracked fieldsv11-v14
  3. Primary endpoints revised (2)
    • Eligibility criteria expanded, about 466 words
    • Secondary endpoints shortened, about 28 words
    • Study description expanded, about 4 words
    v10
  4. Re-verified, no change to tracked fieldsv9
  5. Enrollment target: 999 to 1
    • Primary and study completion dates: Dec 2024 to Dec 31, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v8
  6. Primary and study completion dates: Oct 31, 2024 to Dec 2024v7
  7. Primary and study completion dates: Aug 30, 2024 to Oct 31, 2024v6
  8. Primary endpoints revised (2)v5 Show 5 more changesShow less
    • Interventions: Pfizer-BioNTech COVID-19 bivalent mRNA vaccine (Biological) to Pfizer-BioNTech COVID-19 mRNA vaccine (Biological)
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: 12 to 2
    • Study description expanded, about 228 words
    • Study title revised
  9. Re-verified, no change to tracked fieldsv4
  10. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Enrollment target: 18000000 to 999
    • Primary and study completion dates: Oct 31, 2023 to Aug 30, 2024
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 15, 2023 to Oct 23, 2023
  11. Start date: Jun 5, 2023 to Sep 15, 2023
    • Primary and study completion dates: Aug 31, 2023 to Oct 31, 2023
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: * to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. * to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.
Trial Details
NCT Number NCT05876377
Lead Sponsor Pfizer
Conditions
(from sponsor)		 SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Related terms COVID-19, Post-Acute COVID-19 Syndrome
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov